Data Sheet 1_Oral mucositis risk with EGFR tyrosine kinase inhibitor monotherapies and combination regimens in non-small cell lung cancer: a systematic review and network meta-analysis.pdf

Introduction and aims<p>Oral mucositis (OM) impairs quality of life, necessitates dose modification, and disrupts treatment continuity in patients receiving EGFR tyrosine kinase inhibitors (EGFR-TKIs), yet comparative OM risks across monotherapies and combination regimens remain poorly defined.</p>Methods<p>PubMed, Embase, Web of Science, the Cochrane Library, and ClinicalTrials.gov were searched from inception to June 13, 2026, for phase II or III randomized controlled trials.

Bayesian random-effects network meta-analyses estimated odds ratios (ORs) with 95% credible intervals (CrIs) for any-grade and grade ≥3 OM. Treatments were ranked using the surface under the cumulative ranking curve (SUCRA).</p>Results<p>Sixty-three trials involving 21,845 participants were included. Compared with chemotherapy, higher odds of any-grade OM were observed with afatinib plus cetuximab (OR 11.97, 95% CrI 2.27–65.45), afatinib (OR 9.73, 95% CrI 3.75–26.50), dacomitinib (OR 5.12, 95% CrI 1.71–16.00), and erlotinib plus chemotherapy (OR 2.84, 95% CrI 1.27–6.53), with low-, high-, moderate-, and very-low-certainty evidence, respectively; for grade ≥3 OM, with afatinib plus cetuximab (OR 13.91, 95% CrI 1.55–199.26), afatinib (OR 8.80, 95% CrI 1.37–100.11), and mobocertinib (OR 8.12, 95% CrI 1.14–97.77), all supported by moderate-certainty evidence.